Fidelity Investments’s Aquestive Therapeutics AQST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24.2K Buy
5,822
+326
+6% +$1.37K ﹤0.01% 4593
2026
Q1
$22.8K Sell
5,496
-9,413
-63% -$38.2K ﹤0.01% 4458
2025
Q4
$96.3K Buy
14,909
+10,055
+207% +$62.7K ﹤0.01% 3763
2025
Q3
$27.1K Buy
4,854
+2,524
+108% +$10.9K ﹤0.01% 4236
2025
Q2
$7.71K Sell
2,330
-17
-0.7% -$49 ﹤0.01% 4602
2025
Q1
$6.8K Sell
2,347
-73,298
-97% -$222K ﹤0.01% 4613
2024
Q4
$269K Buy
75,645
+75,104
+13,882% +$346K ﹤0.01% 3156
2024
Q3
$2.69K Buy
541
+511
+1,703% +$1.99K ﹤0.01% 4740
2024
Q2
$77 Sell
30
-70
-70% -$234 ﹤0.01% 4994
2024
Q1
$426 Buy
+100
New +$333 ﹤0.01% 4860
2023
Q3
Sell
-25
Closed -$41 5273
2023
Q2
$41 Buy
+25
New +$45 ﹤0.01% 5049
2021
Q3
Sell
-1
Closed 4299
2021
Q2
$0 Buy
+1
New +$4 ﹤0.01% 4204
2021
Q1
Sell
-400
Closed -$2K 3954
2020
Q4
$2K Buy
+400
New +$2.4K ﹤0.01% 3567

Other funds holding AQST

Fidelity Investments's AQST Position: Q2 2026 in Review

Fidelity Investments increased its Aquestive Therapeutics (AQST) stake by 5.9% in Q2 2026, buying an estimated $1.37K and bringing the position to 5,822 shares worth $24.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4593.

Fidelity Investments first reported a position in AQST in Q4 2020 and has held it in 13 quarters since. The position peaked at $269K in Q4 2024. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Fidelity Investments held 5,822 shares of Aquestive Therapeutics worth $24.2K as of Q2 2026.
  • Fidelity Investments bought 326 Aquestive Therapeutics shares in Q2 2026, an estimated $1.37K.
  • Aquestive Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4593 holding.
  • Fidelity Investments first reported a position in Aquestive Therapeutics in Q4 2020 and has held it in 13 quarters since.
  • Fidelity Investments's Aquestive Therapeutics position peaked at $269K in Q4 2024.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.